Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Minneapolis, MN, Jan. 06, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) today announced that it will be presenting at the 8th Annual Biotech Showcase(TM) to be held January 11-13, 2016 in San Francisco, California.
Event: Biotech Showcase 2016
Location: Parc 55 Hilton Hotel, San Francisco
Date: Tuesday January 12, 2016
Time: 11:30 AM (PST)
BioSig Executive Chairman, Ken Londoner will deliver the Company’s corporate presentation and discuss recent business highlights. To arrange a meeting with management, please contact Robert Haag at [email protected] or 1-866-976-4784.
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EPs in identifying ablation targets -- areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
- Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
- HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Contact: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. [email protected] 917-370-9817 Robert Haag Managing Partner IRTH Communications [email protected] 866-976-4784
